peptide sciences tirzepatide review TIRZ Compounded Tirzepatide Weight Loss Program

The risk for thyroid cancer over a maximum of 8 years of follow-up did not differ between GLP-1 medication users and adults using an SGLT2 inhibitor, DPP-IV inhibitor or sulfonylurea, though GLP-1 users did have a higher thyroid cancer risk during the first year of therapy

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY)

et al., 2024) (Table 3)

Accessed October 25, 2024

Semaglutide and tirzepatide have different receptor binding profiles, different potencies, and different side effect patterns

For weight management, NICE recommends these medications as an adjunct to lifestyle modification in specialist weight management services, with specific BMI thresholds (typically 35 kg/m or 32.5 kg/m in certain ethnic groups) with comorbidities, and usually for time-limited periods (up to 2 years for semaglutide)